Compound
D1107 | tamsulosin hydrochloride
| Toxicity | Dose | Time | Species | Model | Method | Action | Positive criterion | Reference |
|---|---|---|---|---|---|---|---|---|
| MEMBRANE POTENTIAL | 27.20±2.92 | human | qHTS-HepG2 | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | 30.83 | human | HepG2 | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | 25.14±8.04 | rat | hepatocytes | MMP assay | decrease | IC50 | 163 | |
| Pictogram | Signal | Statements | Precautionary Statement Codes |
|---|---|---|---|
 |
Warning |
Aggregated GHS information provided by 132 companies from 10 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. H302 (99.24%): Harmful if swallowed [Warning Acute toxicity, oral] H315 (34.85%): Causes skin irritation [Warning Skin corrosion/irritation] H319 (34.85%): Causes serious eye irritation [Warning Serious eye damage/eye irritation] H335 (34.09%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure Respiratory tract irritation] Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. |
P261, P264, P270, P271, P280, P301+P312, P302+P352, P304+P340, P305+P351+P338, P312, P321, P330, P332+P313, P337+P313, P362, P403+P233, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.) |
| Organism | Test type | Route | Dose (normalized dose) | Effect | Source |
|---|---|---|---|---|---|
| rat | LD50 | intravenous | 70mg/kg (70mg/kg) | Kiso to Rinsho. Clinical Report. Vol. 24, Pg. 5071, 1990. | |
| mouse | LD50 | subcutaneous | 254mg/kg (254mg/kg) | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 35, Pg. 2169, 1993. | |
| rat | LD50 | oral | 650mg/kg (650mg/kg) | Kiso to Rinsho. Clinical Report. Vol. 24, Pg. 5071, 1990. | |
| mouse | LD50 | intravenous | 98mg/kg (98mg/kg) | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 35, Pg. 2169, 1993. | |
| mouse | LD50 | oral | 1023mg/kg (1023mg/kg) | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 35, Pg. 2169, 1993. | |
| rat | LD50 | subcutaneous | 347mg/kg (347mg/kg) | Kiso to Rinsho. Clinical Report. Vol. 24, Pg. 5071, 1990. | |
| dog | LD | oral | > 1gm/kg (1000mg/kg) | Kiso to Rinsho. Clinical Report. Vol. 24, Pg. 5085, 1990. | |
| (-)-(R)-5-(2-((2-(o-Ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide monohydrochloride | (-)-LY 253352 | (-)-ly253352 |
| (R)-(-)-YM12617;LY253351 | (R)-5-(2-((2-(2-ETHOXYPHENOXY)ETHYL)AMINO)PROPYL)-2-METHOXYBENZENESULFONAMIDE HCL | (R)-5-(2-((2-(2-Ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide hydrochloride |
| (R)-5-(2-((2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide monohydrochloride | (R)-5-(2-(2-(2-ethoxyphenoxy)ethylamino)propyl)-2 | (R)-5-(2-(2-(2-ethoxyphenoxy)ethylamino)propyl)-2-methoxybenzenesulfonamide hydrochloride |
| 106463-17-6 | 11SV1951MR | 2-methoxy-5-[3,3,3-trideuterio-2-[2-(2-ethoxyphenoxy)ethylamino]propyl]benzenesulfonamidehydrochloride |
| 463T176 | 5-[(2R)-2-[2-(2-ethoxyphenoxy)ethylamino]propyl]-2-methoxybenzenesulfonamide;hydrochloride | 5-[(2R)-2-[[2-(2-Ethoxyphenoxy)ethyl]amino]propyl]-2-benzenesulfonamide hydrochloride |
| 5-[(2R)-2-[[2-(2-Ethoxyphenoxy)ethyl]amino]propyl]-2-methoxybenzenesulfonamide hydrochloride | 5-[(2R)-2-{[2-(2-Ethoxyphenoxy)ethyl]amino}propyl]-2-methoxybenzene-1-sulfonamide--hydrogen chloride (1/1) | 5-[(2R)-2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl]-2-methoxybenzenesulfonamide hydrochloride |
| 5-[(R)-2-[2-(2-Ethoxyphenoxy)ethylamino]propyl]]-2-methoxybenzenesulfonamide Hydrochloride | A14936 | AB0013408 |
| AK124398 | AKOS015895342 | AKOS015995287 |
| API0001417 | Alna | AlnaOCAS |
| Amsulosin Hydrochloride;Tamsulosin hydrochloride | Amsulosin hydrochloride | BCP0726000042 |
| BG0475 | BS-1019 | Benzenesulfonamide, 5-(2-((2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxy-, monohydrochloride, (R)- |
| Benzenesulfonamide, 5-(2-((2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxy-,monohydrochloride, (R)-; | C20H28N2O5S.HCl | C20H29ClN2O5S |
| CAS-106463-17-6 | CC-34638 | CHEBI:9399 |
| CHEMBL1200914 | CS-2897 | Certified Reference Material |
| D01024 | DSSTox_CID_26628 | DSSTox_GSID_46628 |
| DSSTox_RID_81777 | DTXSID2046628 | EU-617 |
| Expros | FT-0631038 | FT-0674803 |
| Flomax | Flomax (TN) | Flomax MR |
| Flomax hydrochloride | H991 | HY-B0661A |
| Harnal | Harnal (TN) | Harnalidge OCAS |
| Josir | KS-00000H3T | LS-31577 |
| LY-253351 | LY253351 | MFCD00922997 |
| MLS003899197 | MP-0769 | NCGC00167442-01 |
| NCGC00167442-03 | Omic | Omix |
| Omnic | Pradif | PubChem18241 |
| Q-201777 | Q27108379 | R-(-)-5-(2-((2-(2-Ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide hydrochloride |
| R-(-)-YM-12617 | RTX-011084 | SC-17028 |
| SCHEMBL23428 | SMR002543366 | ST24026438 |
| Secotex | TAMSULOSIN HYDROCHLORIDE | Tamsulosin (hydrochloride) |
| Tamsulosin HCl | Tamsulosin Hydrochloride,(S) | Tamsulosin hydrochloride (JP17/USAN) |
| Tamsulosin hydrochloride [USAN:JAN] | Tamsulosin hydrochloride [USAN:USP:JAN] | Tamsulosin hydrochloride, >=98% (HPLC) |
| Tamsulosin hydrochloride, British Pharmacopoeia (BP) Reference Standard | Tamsulosin hydrochloride, European Pharmacopoeia (EP) Reference Standard | Tamsulosin hydrochloride, Pharmaceutical Secondary Standard |
| Tamsulosin hydrochloride, United States Pharmacopeia (USP) Reference Standard | Tamsulosin-hydrochloride | Tamsulosina hydrochloride |
| Tamsulosinum hydrochloride | Tox21_112446 | Tox21_112446_1 |
| UNII-11SV1951MR | Urolosin | Y-617 |
| YM 617 | YM-12617-1 | YM-617 |
| YM617 | ZZIZZTHXZRDOFM-XFULWGLBSA-N | s4729 |
| tamsulosin.HCl | tamsulosine hydrochloride |